Generate Biomedicines prices IPO at $16 per share

Generate Biomedicines, Inc. (NASDAQ: GENB) announced the pricing of its initial public offering of 25 million shares of common stock at $16.00 per share. The clinical-stage generative biology company expects to raise $400 million in gross proceeds before underwriting discounts and commissions.

The company has granted underwriters a 30-day option to purchase up to an additional 3.75 million shares at the IPO price, less underwriting discounts and commissions. All shares in the offering are being sold by Generate Biomedicines.

The company's common stock is expected to begin trading on the Nasdaq Global Select Market on February 27, 2026, under the ticker symbol "GENB." The offering is expected to close on March 2, 2026, subject to customary closing conditions.

Goldman Sachs & Co. LLC and Morgan Stanley are serving as joint lead book-running managers for the offering. Piper Sandler, Guggenheim Securities, and Cantor are acting as book-running managers.

Generate Biomedicines describes itself as a company pioneering artificial intelligence applications in biotechnology and drug design and development. The company is based in Somerville, Massachusetts.

The U.S. Securities and Exchange Commission declared the registration statement for the securities effective on February 26, 2026. The offering is being conducted solely through a prospectus, with copies available from the underwriters upon request.

You May Also Be Interested In

• Gores Holdings XI prices $312M IPO on Nasdaq
• Cantor Equity Partners VII raises $250M in Nasdaq IPO
• InterCure raises NIS 22M in private placement at a share premium